NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

BioNTech SE (BNTX) Stock Analysis

BioNTech SE (BNTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BNTX

$103.76

+$0.88 (+0.86%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BNTX with… →

BNTX Key Statistics

As of Sep 4, 2026
Trading
Open
$102.78
Previous Close
$102.88
Day's Range
102.33–104.82
52-Week Range
79.52–124.00
Volume
626.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.29
Valuation
Market Cap
$26.06B
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.05
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.84
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.84
Financials (FY)
Revenue (FY)
$2.87B+4.32%
Net Income (FY)
−$1.14B
Profit marginThe share of revenue left as profit after all costs and taxes.
−63.64%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
251.20M
1-Year Return
+0.25%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
1.22M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BNTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+8.99%
2025−16.45%
2024+7.97%
2023−29.74%
2022−40.96%
2021+216.24%
2020+140.61%
2019 (partial year)+137.92%

As of September 4, 2026.

BNTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.87B−$1.14B−39.6%
2024$2.75B−$665.30M−24.2%
2023$3.82B$930.30M24.4%
2022$17.31B$9.43B54.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.87B$2.23B−$640.70M−$1.14B−39.6%
2024$2.75B$2.21B−$709.40M−$665.30M−24.2%
2023$3.82B$3.22B$875.60M$930.30M24.4%
2022$17.31B$14.32B$12.30B$9.43B54.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BNTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricBNTXBiotechnology medianvs median
P/S ratio9.8415.2636% below
Profit margin−63.64%0.00%63.6 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 19 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BioNTech SE (BNTX) carries a market capitalisation of $26.06B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 7,807.

The 52-week range on file runs from $79.52 to $124.00. BNTX last closed at $103.76 on September 4, 2026. That is +$0.88 (+0.86%) against the previous close. The latest close sits 30.48% above that 52-week low.

Financial Health

In fiscal 2025, BioNTech SE reported revenue of $2.87B. That is +4.32% against the prior fiscal year, when revenue was $2.75B. The same year closed with a net loss of $1.14B. Profit margin runs at −63.64%. That is 63.6 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −7.84.

Across the 4 fiscal years on file, revenue moves from $17.31B in 2022 to $2.87B in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.05. The price-to-sales ratio is 9.84. On price-to-sales that is 35.56% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.29. Annualized volatility over the trailing 6 years is 58.16%. Over the trailing twelve months the price has returned +0.25%. Across 5 years the annualized return works out at −20.65%.

Growth & Income

No dividend is on file for BNTX.

Across the complete calendar years on file, 2021 returned +216.24% and 2022 returned −40.96%. Of the 6 complete calendar years on file, 3 finished higher. 2026 is still running; the price is +8.99% year to date.

Peer Comparison

BioNTech SE (BNTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioNTech SE BNTX $26.06B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. BioNTech SE has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Visit website →